**Abstract**

**Objective:** Clozapine is an atypical antipsychotic drug famous for its low propensity to cause extrapyramidal symptoms, one of those mainly being tardive dyskinesia(TD). Mechanism underlying this so-called anti-TD property of clozapine is largely in a veil as well as the pathophysiology of TD itself. Furthermore, terminologies referring to TDs of varying mechanisms heretofore lack consensus among clinicians. This study introduces a case of newly emergent TD after clozapine usage, and discusses the plausible mechanism of how TD develops in varying clinical situations.

**Methods & Results:** We reviewed a case of a 57-year-old female with schizophrenia. She had been treated intermittently with haloperidol and a few types of small-dosage atypical antipsychotics for 5 years. She was admitted to closed ward for worsening of psychotic symptoms. Prior to that, she had been medication-free for at least 1 month. We first used paliperidone for a month, and medication was changed to clozapine due to unsatisfactory response. 1.5 month into clozapine use, the patient developed a severe degree(grade 4 of Abnormal Involuntary Movement Scale, or AIMS) of TD in whole body including orofacial, truncal, limb areas. Clozapine was drastically reduced and TD ameliorated to minimal degree(AIMS grade 1) in a 3-months-time, but still persisting.

**Conclusion:** The emergence of TD in this case cannot best be explained by withdrawal, covert or spontaneous TD like most of the previous case reports of TD after clozapine use. Rather, the relatively acute onset of TD and the risk factors for TD the patient held sums up for the likeliness of association with neuronal degenerative changes in striatum. Previous genetic and epidemiologic evidences suggest for possible association of genetic alteration. This calls for further studies regarding pathophysiology of TD and according genetic markers.
